Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 329.00 | |
5 mg | In stock | $ 798.00 | |
10 mg | In stock | $ 1,090.00 | |
25 mg | In stock | $ 1,650.00 | |
50 mg | In stock | $ 2,230.00 | |
100 mg | In stock | $ 2,930.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 995.00 |
Description | OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively. |
Targets&IC50 | α2C-adrenoceptor:55 nM (ki), α2B-adrenoceptor:285 nM (ki), α2A-adrenoceptor:2040 nM (ki) |
In vitro | OPC-28326 augments microvessel growth and improves endothelial tube formation. OPC-28326 dose-dependently induces phosphorylation of eNOS and Akt without affecting total amounts of eNOS and Akt in HAECs[1]. |
In vivo | OPC-28326 improves blood flow recovery in murine hindlimb ischemia and increases the number of capillaries in the ischemic leg[1]. In rats, intravenous administration of OPC-28326 (3 - 30 mg/kg) and yohimbine (0.3 - 3 mg/kg) results in a dose-dependent rightward shift in the pressor dose-response curve induced by B-HT 920 without affecting the mydriasis[2]. |
Molecular Weight | 421.58 |
Formula | C26H35N3O2 |
CAS No. | 167626-17-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.22 mg/mL (10 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
OPC-28326 167626-17-7 GPCR/G Protein Neuroscience Adrenergic Receptor OPC28326 OPC 28326 inhibitor inhibit